Exforge antitrust settlement caps Novartis’ year of legal disputes
Pharmaceutical Technology
JANUARY 6, 2023
According to the legal documents , the plaintiffs accused the companies of “violating federal antitrust laws, alleging “per se” and “rule of reason” violations”. At the centre of the case was Gilenya’s ‘405 patent, which details methods for treating relapsing multiple sclerosis with a specific dosage of the drug.
97 
Let's personalize your content